ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
18/04/2025
Voltar para busca
Dado oficial do USPTO
SIPORE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
24/04/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10
Data de depósito
01/06/2018
Data de registro
03/03/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
03/03/2020
Última transação
24/04/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
98
Localização do titular
SE
Examinador
INGRAM,KYLE G
Unidade examinadora
N70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Sigrid Therapeutics AB
Representantes
Bradley L. Cohn Pattishall, McAuliffe, Newbury, Hilliard
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Dietetic preparations adapted for medical use; dietetic substances in the nature of tabletscapsulesliquid formulationsdrinksshotsshakesgelspowders and suspensions adapted for medical use; pharmaceuticals and natural remedies for the treatment and prevention of obesitybeing overweightprediabetesdiabetesglycemic control and for the improvement of overall metabolic health; preparations for use in naturopathy for the treatment and prevention of obesitybeing overweightprediabetesdiabetesglycemic control and for the improvement of overall metabolic health; nutritional supplements; chemical preparations for medical purposes for the treatment and prevention of obesitybeing overweightprediabetesdiabetesglycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and chemico- pharmaceutical preparations for the treatment and prevention of obesitybeing overweightprediabetesdiabetesglycemic control and for the improvement of overall metabolic health; dietary and nutritional supplements; health food supplements for persons with special dietary requirements; chemical preparations for pharmaceutical purposes for the treatment and prevention of obesitybeing overweightprediabetesdiabetesglycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and substances for glycemic control; pharmaceutical preparations and substances for the prevention and treatment of prediabetesdiabetes and for the improvement of overall metabolic health; dietetic preparations and substances for glycemic control; dietetic preparations and substances for the prevention and treatment of prediabetesdiabetes and for the improvement of overall metabolic health; dietary and nutritional supplements for glycemic control; dietary and nutritional supplements for the prevention and treatment of prediabetesdiabetes and for the improvement of overall metabolic health; pharmaceutical preparations in the form of tabletscapsulesliquid formulationsdrinksshotsshakesgelspowders and suspensions for use in glycemic control; pharmaceutical preparations in the form of tabletscapsulesliquid formulationsdrinksshotsshakesgelspowders and suspensions for use in the prevention and treatment of prediabetesdiabetes and for the improvement of overall metabolic health; pharmaceutical preparations and substancesdietary and nutritional substances in the form of tabletscapsulesliquid formulationsdrinksshotsshakesgelspowders and suspensionsall for use in the treatment and regulation of obesitybody weightbody fatbody compositionbody weight circumferencecholesterol and LDL cholesterol levelsliver diseasesteatohepatitisinfantile colicgut microbiotainsulin levels and resistanceblood lipidsdiarrheaconstipationcolitis; pharmaceutical preparations and substancesdietary and nutritional substances in the form of tabletscapsulesliquid formulationsdrinksshotsshakesgelspowders and suspensionsall for use in the treatment and regulation of intestinal injury or inflammationCrohn's diseasecardiovascular risk factorspost bariatric surgery patientsnot including products primarily for use in the treatment of angina pectoris and high blood pressure
Classe 10
Surgical and medical devices for the treatment and prevention of obesitybeing overweightprediabetesdiabetesglycemic control and for the improvement of overall metabolic health; capsulated medical devices for the treatment and prevention of obesitybeing overweightprediabetesdiabetesglycemic control and for the improvement of overall metabolic health; medical devices for the treatment and prevention of obesity and being overweightfor use in weight control; medical devices for the treatment and prevention of prediabetesdiabetes and glycemic controlfor the improvement of overall metabolic health; medical devices for use in the prevention and treatment of prediabetes and diabetes; orally administered medical devices for the treatment and prevention of obesitybeing overweightprediabetesdiabetesglycemic control and for the improvement of overall metabolic health; surgical and medical devicescapsulated devices and orally administered medical devices all for use in the treatment and regulation of obesitybody weightbody fatbody compositionbody weight circumferencecholesterol and LDL cholesterol levelsliver diseasesteatohepatitisinfantile colicgut microbiotainsulin levels and resistanceblood lipidsdiarrheaconstipationintestinal injury or inflammationcolitisCrohn's diseasecardiovascular risk factorspost bariatric surgery patients
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/03/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/04/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
29/01/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
24/07/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/07/2020
FIMP
FINAL DISPOSITION PROCESSED
08/07/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/06/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
03/03/2020
GPNX
NOTIFICATION PROCESSED BY IB
20/12/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/12/2019
PUBO
PUBLISHED FOR OPPOSITION
17/12/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/12/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/12/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/11/2019
ALIE
ASSIGNED TO LIE
14/11/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/11/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/11/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/11/2019
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/11/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
13/06/2019
GNFR
FINAL REFUSAL E-MAILED
13/06/2019
CNFR
FINAL REFUSAL WRITTEN
13/06/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/06/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/06/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/06/2019
ATRV
ATTORNEY REVIEW COMPLETED
08/02/2019
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
07/02/2019
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
01/02/2019
RFNT
REFUSAL PROCESSED BY IB
21/12/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/12/2018
RFRR
REFUSAL PROCESSED BY MPU
04/12/2018
MAFR
APPLICATION FILING RECEIPT MAILED
23/11/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
21/11/2018
CNRT
NON-FINAL ACTION WRITTEN
20/11/2018
DOCK
ASSIGNED TO EXAMINER
19/11/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/11/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
15/11/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SIPORE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.